BLAST PHASE CHRONIC MYELOGENOUS LEUKEMIA, BCR-ABL1 POSITIVE
Clinical trials for BLAST PHASE CHRONIC MYELOGENOUS LEUKEMIA, BCR-ABL1 POSITIVE explained in plain language.
Never miss a new study
Get alerted when new BLAST PHASE CHRONIC MYELOGENOUS LEUKEMIA, BCR-ABL1 POSITIVE trials appear
Sign up with your email to follow new studies for BLAST PHASE CHRONIC MYELOGENOUS LEUKEMIA, BCR-ABL1 POSITIVE, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
Genom att skicka in godkänner du våra Användarvillkor
-
New combo shows promise against tough leukemia
Disease control OngoingThis study tests a powerful chemotherapy regimen (Hyper-CVAD) combined with the targeted drug ponatinib in people with a specific type of acute lymphoblastic leukemia (ALL) that has a genetic change called the Philadelphia chromosome. The goal is to see if this combination can be…
Matched conditions: BLAST PHASE CHRONIC MYELOGENOUS LEUKEMIA, BCR-ABL1 POSITIVE
Phase: PHASE2 • Sponsor: M.D. Anderson Cancer Center • Aim: Disease control
Last updated May 26, 2026 08:45 UTC
-
Promising combo tackles tough leukemia
Disease control OngoingThis study tests a new way to treat Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ ALL), a fast-growing blood cancer. It combines low-intensity chemotherapy with targeted drugs (ponatinib and blinatumomab) to kill cancer cells and help the immune system fight …
Matched conditions: BLAST PHASE CHRONIC MYELOGENOUS LEUKEMIA, BCR-ABL1 POSITIVE
Phase: PHASE2 • Sponsor: M.D. Anderson Cancer Center • Aim: Disease control
Last updated May 26, 2026 08:29 UTC
-
New antibody takes aim at Hard-to-Treat blood cancers
Disease control OngoingThis early-phase study tests a new antibody called Hu8F4 in 72 people with advanced blood cancers like leukemia and myelodysplastic syndrome. The main goal is to find a safe dose and check for side effects. Researchers hope the antibody can slow or stop cancer growth.
Matched conditions: BLAST PHASE CHRONIC MYELOGENOUS LEUKEMIA, BCR-ABL1 POSITIVE
Phase: PHASE1 • Sponsor: M.D. Anderson Cancer Center • Aim: Disease control
Last updated May 26, 2026 08:19 UTC
-
New drug cocktail shows promise for Hard-to-Treat leukemias
Disease control OngoingThis study tests a combination of three drugs (decitabine, venetoclax, and ponatinib) in 20 people with Philadelphia chromosome-positive acute myeloid leukemia or chronic myelogenous leukemia that has worsened. The goal is to see how well the drugs work together to control the ca…
Matched conditions: BLAST PHASE CHRONIC MYELOGENOUS LEUKEMIA, BCR-ABL1 POSITIVE
Phase: PHASE2 • Sponsor: M.D. Anderson Cancer Center • Aim: Disease control
Last updated May 19, 2026 11:47 UTC